Stock rating

Search documents
Johnson & Johnson Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Benzinga· 2025-10-10 06:42
Johnson & Johnson (NYSE:JNJ) will release earnings results for the third quarter, before the opening bell on Tuesday, Oct. 14.Analysts expect the New Brunswick, New Jersey-based company to report quarterly earnings at $2.76 per share, up from $2.42 per share in the year-ago period. Johnson & Johnson projects quarterly revenue of $23.76 billion, compared to $22.47 billion a year earlier, according to data from Benzinga Pro.On Tuesday, the U.S. Food and Drug Administration (FDA) approved Johnson & Johnson's S ...
Microsoft (MSFT) is a Top-Ranked Growth Stock: Should You Buy?
ZACKS· 2025-10-08 14:46
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.Zacks Premium includes access to the Zacks Style Scores as well. What are the Zacks Style Sco ...
What You Need To Know Ahead of Nucor's Earnings Release
Yahoo Finance· 2025-10-08 06:56
Charlotte, North Carolina-based Nucor Corporation (NUE) is a leading producer of structural steel, steel bars, steel joists, steel deck, and cold finished bars. With a market cap of $31.1 billion, Nucor operates through steel mills, steel products, and raw materials segments. The steel manufacturer is gearing up to announce its Q3 earnings after the market closes on Monday, Oct. 27. Ahead of the event, analysts expect Nucor to report a profit of $2.16 per share, up 45% from $1.49 per share reported in the ...
Helen of Troy Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Benzinga· 2025-10-07 12:08
Helen of Troy Limited (NASDAQ:HELE) will release earnings results for the second quarter, before the opening bell on Thursday, Oct. 9.Analysts expect the El Paso, Texas-based company to report quarterly earnings at 52 cents per share, down from $1.21 per share in the year-ago period. Helen of Troy projects quarterly revenue of $416.77 million, compared to $474.22 million a year earlier, according to data from Benzinga Pro.On Aug. 13, Helen of Troy named G. Scott Uzzell as its CEO.Helen of Troy shares fell 0 ...
Top Wall Street Forecasters Revamp BlackBerry Expectations Ahead Of Q2 Earnings
Benzinga· 2025-09-24 10:50
BlackBerry Limited BB will release earnings results for the second quarter, before the opening bell on Thursday, Sept. 25.Analysts expect the Waterloo, Canada-based company to report quarterly earnings at 1 cent per share. BlackBerry projects to report quarterly revenue at $122.03 million. It reported $145 million a year earlier, according to data from Benzinga Pro.On Sept. 18, BlackBerry announced it has become the first mobile device management vendor certified by Germany's Federal Office for Information ...
Wall Street Analysts See CRISPR Therapeutics (CRSP) as a Buy: Should You Invest?
ZACKS· 2025-09-11 14:31
Core Viewpoint - The article discusses the reliability of brokerage recommendations, particularly focusing on CRISPR Therapeutics AG (CRSP), and highlights the potential misalignment of interests between brokerage analysts and retail investors [1][5][10]. Group 1: Brokerage Recommendations for CRISPR Therapeutics - CRISPR Therapeutics has an average brokerage recommendation (ABR) of 1.92, indicating a consensus between Strong Buy and Buy, based on 28 brokerage firms [2]. - Out of the 28 recommendations, 15 are classified as Strong Buy, while one is classified as Buy, representing 53.6% and 3.6% of total recommendations respectively [2]. Group 2: Limitations of Brokerage Recommendations - Studies indicate that brokerage recommendations may not effectively guide investors in selecting stocks with the highest price increase potential [5]. - Brokerage firms often exhibit a strong positive bias in their ratings due to vested interests, leading to a disproportionate number of Strong Buy recommendations compared to Strong Sell recommendations [6][10]. Group 3: Zacks Rank as an Alternative Indicator - Zacks Rank categorizes stocks into five groups based on earnings estimate revisions, which are more reliable indicators of near-term stock price performance compared to ABR [8][11]. - The Zacks Rank is updated more frequently and reflects timely changes in earnings estimates, unlike the potentially outdated ABR [13]. Group 4: Current Earnings Estimates for CRISPR Therapeutics - The Zacks Consensus Estimate for CRISPR Therapeutics remains unchanged at -$6.57 for the current year, suggesting stable analyst views on the company's earnings prospects [14]. - Due to the unchanged consensus estimate, CRISPR Therapeutics holds a Zacks Rank of 3 (Hold), indicating a cautious approach despite the Buy-equivalent ABR [15].
Why Archrock Inc. (AROC) is a Top Value Stock for the Long-Term
ZACKS· 2025-08-15 14:41
Company Overview - Archrock Inc. has transitioned from a broader energy services provider to a specialized pure-play compression services company, focusing on natural gas production, processing, and transportation [11] - The company has undergone an operational transformation over the past decade to enhance performance, safety, customer service, and environmental responsibility [11] Zacks Rank and Style Scores - Archrock is currently rated 3 (Hold) on the Zacks Rank, with a VGM Score of B, indicating a solid position but not a strong buy [12] - The Value Style Score for Archrock is B, supported by a forward P/E ratio of 15.29, making it attractive for value investors [12] - Recent upward revisions in earnings estimates by two analysts for fiscal 2025 have increased the Zacks Consensus Estimate by $0.02 to $1.57 per share [12] - Archrock has demonstrated an average earnings surprise of +6.5%, indicating potential for positive performance [12] Investment Consideration - With a solid Zacks Rank and favorable Value and VGM Style Scores, Archrock is recommended for investors' consideration [13]
Lumentum Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Benzinga· 2025-08-12 18:39
Core Viewpoint - Lumentum Holdings Inc. is expected to report significant growth in earnings and revenue for the fourth quarter, indicating a positive outlook for the company [1]. Financial Performance - Analysts predict Lumentum will report quarterly earnings of 81 cents per share, a substantial increase from 6 cents per share in the same quarter last year [1]. - The projected quarterly revenue is $469.92 million, compared to $308.3 million a year earlier, reflecting a strong year-over-year growth [1]. Company Developments - On August 7, Lumentum announced the expansion of its U.S.-based semiconductor facility, which may enhance its production capabilities and market position [2]. Stock Performance - Lumentum shares experienced a slight decline of 1.1%, closing at $115.03 on Monday [3]. Analyst Ratings - Morgan Stanley maintained an Equal-Weight rating and raised the price target from $85 to $92 [8]. - Susquehanna maintained a Positive rating and increased the price target from $95 to $125 [8]. - JP Morgan maintained an Overweight rating and boosted the price target from $100 to $123 [8]. - Wolfe Research initiated coverage with an Outperform rating [8]. - Rosenblatt maintained a Buy rating with a price target of $105 [8].
Moderna Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Benzinga· 2025-08-01 08:37
Core Viewpoint - Moderna is facing challenges due to declining COVID-19 vaccine sales and market uncertainty, leading to workforce reductions and expected financial losses in the upcoming earnings report [2]. Financial Performance - Analysts predict Moderna will report a quarterly loss of $2.97 per share, an improvement from a loss of $3.33 per share a year ago [1]. - Projected quarterly revenue is $112.96 million, down from $241 million a year earlier [1]. Workforce Reduction - Moderna announced plans to reduce its global workforce by approximately 10% by the end of the year [2]. Stock Performance - Following the announcement of workforce reductions, Moderna shares fell by 8.1%, closing at $29.56 [2]. Analyst Ratings - JP Morgan analyst Jessica Fye maintained an Underweight rating and reduced the price target from $33 to $26 [8]. - Evercore ISI Group analyst Cory Kasimov maintained an In-Line rating and cut the price target from $50 to $32 [8]. - Morgan Stanley analyst Matthew Harrison maintained an Equal-Weight rating and lowered the price target from $39 to $32 [8]. - Citigroup analyst Geoff Meacham initiated coverage with a Neutral rating and a price target of $40 [8]. - Argus Research analyst John Eade downgraded the stock from Buy to Hold [8].
Why LATAM (LTM) is a Top Growth Stock for the Long-Term
ZACKS· 2025-07-31 14:46
Company Overview - LATAM Airlines is the leading airline in Latin America, headquartered in Santiago, Chile [11] - The company filed for Chapter 11 bankruptcy on May 26, 2020, and successfully emerged from bankruptcy on November 3, 2022, as part of a financial restructuring to reduce debt and adapt to challenges from the COVID-19 pandemic [11] - Post-bankruptcy, LATAM emerged with approximately $2.2 billion in liquidity and a 35% reduction in debt, alongside a more resilient operational structure [11] Investment Potential - LATAM Airlines holds a 2 (Buy) rating on the Zacks Rank, with a VGM Score of A, indicating strong investment potential [12] - The company is particularly appealing to growth investors, with a Growth Style Score of A, forecasting year-over-year earnings growth of 29.1% for the current fiscal year [12] - An analyst has revised their earnings estimate upwards for fiscal 2025, with the Zacks Consensus Estimate increasing by $0.05 to $4.17 per share [12] - LATAM has an average earnings surprise of +4%, further enhancing its attractiveness to investors [12] Conclusion - With a solid Zacks Rank and top-tier Growth and VGM Style Scores, LATAM Airlines is recommended for investors' consideration [13]